Eileen M. O'Reilly

Eileen O'Reilly is a globally recognized leader in upper GI malignancies — pancreatic cancer, biliary tract cancers (cholangiocarcinoma and gallbladder cancer), and hepatocellular carcinoma — with one of the most extensive clinical trial portfolios in these disease areas. As Section Head for Hepatopancreaticobiliary Cancers and holder of the Winthrop Rockefeller Chair at Memorial Sloan Kettering Cancer Center, she has been instrumental in establishing new systemic therapy standards and translating molecularly targeted agents into clinical practice. O'Reilly was a key investigator in trials that established FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, leucovorin) and gemcitabine plus nab-paclitaxel as standard first-line regimens for metastatic PDAC. More recently, she played a central role in the development and clinical testing of the NALIRIFOX regimen (liposomal irinotecan + oxaliplatin + 5-FU/LV) through the NAPOLI-3 trial, a phase III study that demonstrated superior overall survival versus gemcitabine plus nab-paclitaxel in previously untreated metastatic PDAC. NAPOLI-3 established NALIRIFOX as a new first-line standard, representing one of the most significant advances in PDAC systemic therapy in recent years. In biliary tract cancers, O'Reilly has been a leading investigator in precision oncology clinical trials targeting actionable molecular alterations. She has contributed to trials evaluating FGFR inhibitors — including pemigatinib and futibatinib — in FGFR2 fusion-positive cholangiocarcinoma, which led to regulatory approvals that transformed treatment of this genomically defined subset. She has also been involved in trials of IDH1 inhibitors (ivosidenib) in IDH1-mutant cholangiocarcinoma and HER2-directed therapies in HER2-amplified biliary tract cancers, building a comprehensive framework of molecularly guided therapy for these rare but molecularly heterogeneous tumors. O'Reilly's research has spanned stromal targeting strategies, DNA damage response inhibitors (PARP inhibitors in BRCA-mutant PDAC), and immunotherapy combinations in pancreatic cancer. She is a co-investigator on multiple National Cancer Institute Specialized Programs of Research Excellence (SPORE) grants and serves on the editorial boards of leading oncology journals.

Eileen O'Reilly 是上腹部消化系统恶性肿瘤领域（胰腺癌、胆道癌及肝细胞癌）的全球公认领袖，在纪念斯隆-凯特琳癌症中心担任肝胰胆道癌症部门负责人。她在建立新全身治疗标准方面发挥了关键作用。 她是NAPOLI-3 III期试验的核心研究者，该试验确立了NALIRIFOX方案作为转移性PDAC的一线新标准。在胆道癌领域，她领导了针对FGFR2融合阳性胆管癌的FGFR抑制剂（培咪替尼、futibatinib）以及IDH1突变胆管癌的IDH1抑制剂（艾伏尼布）临床试验，推动了多个监管批准。